GlassScriptPhysician profile
Roger Anthony Bartz
NPI 1053502237
$1,898.06
in general payments reported to CMS, 2019-2025
23 companies · $277 in 2025
The $277 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $127 · 2021: $162 · 2022: $138 · 2023: $274 · 2024: $453 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $279.50 | 2021-2024 | Azstarys |
| Sanofi Pasteur INC. | $276.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $169.81 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $158.40 | 2020-2022 | |
| Shire North American Group INC | $156.74 | 2019 | |
| Ironshore Pharmaceuticals INC. | $132.93 | 2024 | |
| Glaxosmithkline, LLC. | $120.94 | 2019-2025 | Pediarix, Bexsero, Rotarix |
| Cumberland Pharmaceuticals, INC. | $95.49 | 2019-2020 | |
| Seqirus USA INC | $77.83 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Cranial Technologies, INC | $74.28 | 2019-2024 | Doc Band |
| Collegium Pharmaceutical, INC. | $71.58 | 2025 | Jornay Pm |
| Ironwood Pharmaceuticals, INC | $40.58 | 2024 | |
| Sanofi-Aventis U.S. LLC | $32.79 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $27.38 | 2024 | Zoryve |
| Neos Therapeutics, LP | $26.42 | 2019-2023 | Cotempla Xr-Odt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $26.33 | 2025 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals LP | $24.56 | 2023 | Flumist Quadrivalent |
| Organon LLC | $23.71 | 2025 | |
| Pharming Healthcare, INC. | $19.91 | 2025 | Ruconest |
| Vertical Pharmaceuticals, LLC | $19.56 | 2019 | |
| Pfizer INC. | $14.80 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.35 | 2024 | Ycanth |
| Alexion Pharmaceuticals, INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Bartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.